131I联合甲磺酸阿帕替尼治疗分化型甲状腺癌肺转移的短期疗效及安全性研究

doi:10.11904/j.issn.1002-3070.2022.04.006

实用肿瘤学杂志 ›› 2022, Vol. 36 ›› Issue (4): 323-326.doi: 10.11904/j.issn.1002-3070.2022.04.006

¹³¹I联合甲磺酸阿帕替尼治疗分化型甲状腺癌肺转移的短期疗效及安全性研究

赵盛雯, 吴桐

黑龙江省中医药科学院影像科(哈尔滨 150036)

收稿日期:2022-02-19 修回日期:2022-06-29 出版日期:2022-08-28 发布日期:2022-08-29
通讯作者: 吴桐,E-mail:wutong19@88.com
作者简介:赵盛雯,女,(1986-),本科,主治医师,从事影像学与核医学的相关研究。

Short-term efficacy and safety of ¹³¹I combined with apatinib in the treatment of differentiated thyroid cancer with lung metastasis

ZHAO Shengwen, WU Tong

Department of Imaging,Heilongjiang Academy of Traditional Chinese Medicine,Harbin 150036,China

Received:2022-02-19 Revised:2022-06-29 Online:2022-08-28 Published:2022-08-29

摘要/Abstract

摘要： 目的探讨¹³¹I联合甲磺酸阿帕替尼治疗分化型甲状腺癌肺转移的短期疗效及安全性。方法回顾分析2018年10月—2020年10月于我院就诊治疗的分化型甲状腺癌肺转移患者57例,分为对照组(n=30)和联合治疗组(n=27),对照组单纯使用¹³¹I治疗,联合治疗组行¹³¹I联合阿帕替尼治疗。每半年观察并记录两组患者的甲状腺球蛋白(Thyroglobulin,Tg)水平、靶病灶(Target lesions,TL)的基线直径变化情况及靶病灶浓聚放射性灶计数/本底计数(Concentration range count/background count,C/B)的变化情况,同时记录两组患者的不良反应情况。结果随访结束后联合治疗组Tg水平(36.34±19.72 μg/L)较对照组(122.18±22.98 μg/L)明显降低,差异具有统计学意义(P＜0.001);联合治疗组TL的直径均值(3.55±0.39 mm)较对照组(14.01±1.44 mm)明显缩小,差异具有统计学意义(P＜0.001)。24个月后,联合治疗组DCR和ORR高于对照组(P＜0.01)。联合治疗组C/B值(2.98±0.54)较对照组(25.45±3.00)明显降低,差异具有统计学意义(P＜0.001)。联合治疗组阿帕替尼常见的不良反应为手足综合征6例,高血压4例,皮疹2例,未观察到与阿帕替尼相关的Ⅲ级以上严重不良反应。结论 ¹³¹I联合甲磺酸阿帕替尼治疗分化型甲状腺癌肺转移疗效确切,具有明显的缩瘤效果,达到较高的生化缓解率,同时副作用轻微可控,安全性较高。

关键词: ¹³¹I, 甲磺酸阿帕替尼, 分化型甲状腺癌, 肺转移, 甲状腺球蛋白

Abstract: Objective The Objective of our study was to investigate the short-term efficacy and safety of ¹³¹I combined with apatinib in the treatment of lung metastasis from differentiated thyroid cancer.Methods A retrospective analysis of 57 patients with lung metastases from differentiated thyroid cancer who were treated in our department from October 2018 to October 2020 were divided into the control group(n=30)and the combined treatment group(n=27).The control group was treated with ¹³¹I alone,and the combination group was treated with ¹³¹I combined with apatinib.In both groups of patients,the levels of thyroglobulin(Tg)and baseline diameter were observed and recorded every six months.The changes of baseline diameter changes of target lesions(TL)and concentration range count/background count(C/B)were observed and recorded every six months.At the same time,the adverse reactions of patients in the two groups were recorded.Results After the follow-up,the level of Tg in the combined treatment group(36.34±19.72 μg/L)was significantly lower than that in the control group(122.18±22.98 μg/L),and the difference was statistically significant(P＜0.001).The mean diameter of TL in the combined treatment group(3.55±0.39 mm)was significantly smaller than that of the control group(14.01±1.44 mm),and the difference was statistically significant(P＜0.001).After 24 months,DCR and ORR in the combined treatment group were higher than those in the control group(P＜0.01).The C/B value of the combined treatment group(2.98±0.54)was significantly lower than that of the control group(25.45±3.00),and the difference was statistically significant(P＜0.001).The common adverse reactions of apatinib in the combined treatment group were hand-foot syndrome(6 cases),hypertension(4 cases),and rash(2 cases).No serious adverse reactions of grade Ⅲ or above related to apatinib were observed.Conclusion ¹³¹I combined with apatinib is effective in the treatment of lung metastasis from differentiated thyroid cancer,has obvious tumor shrinkage effect and achieves a high biochemical remission rate,while the side effects are mild and controllable,and the safety is high.

Key words: ¹³¹I, Apatinib, Differentiated thyroid cancer, Lung metastasis, Thyroglobulin

中图分类号:

R736.1

赵盛雯, 吴桐. ¹³¹I联合甲磺酸阿帕替尼治疗分化型甲状腺癌肺转移的短期疗效及安全性研究[J]. 实用肿瘤学杂志, 2022, 36(4): 323-326.

ZHAO Shengwen, WU Tong. Short-term efficacy and safety of ¹³¹I combined with apatinib in the treatment of differentiated thyroid cancer with lung metastasis[J]. Journal of Practical Oncology, 2022, 36(4): 323-326.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2022.04.006

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2022/V36/I4/323

参考文献

1 Schlumberger M,Leboulleux S.Current practice in patients with differentiated thyroid cancer[J].Nat Rev Endocrinol,2021,7(3):176-188.
2 Zehnder AM,Swift LA,Sundaram A,et al.Clinical features,treatment,and outcomes of cutaneous and oral squamous cell carcinoma in avian species[J].J Am Vet Med Assoc,2018,252(3):309-315.
3 Schlumberger M,Tahara M,Wirth LJ,et al.Lenvatinib versus placebo in radioiodine-refractory thyroid cancer[J].N Engl J Med,2015,12,372(7):621-630.
4 Ghosh RD,Ghuwalewala S,Das P,et al.MicroRNA profiling of cisplatin-resistant oral squamous cell carcinoma cell lines enriched with cancer-stem-cell-like and epithelial-mesenchymal transition-type features[J].Sci Rep,2016,6:23932.
5 Cabanillas ME,Takahashi S.Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer[J].Semin Oncol,2019,46(1):57-64.
6 Wiegering A,Korb D,Thalheimer A,et al.E7080(Lenvatinib),a multi-targeted tyrosine kinase inhibitor,demonstrates antitumor activities against colorectal cancer xenografts[J].Neoplasia,2014,16(11):972-981.
7 Chi Y,Gao M,Zhang Y,et al.LBA88 Anlotinib in locally advanced or metastatic radioiodine refractory differentiated thyroid carcinoma:a randomized,double-blind,multicenter phase II trial[J].Ann Oncol,2020,31(6):1215.
8 Brose MS,Worden FP,Newbold KL,et al.Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT trial[J].J Clin Oncol,2017,35(23):2692-2699.
9 Zhao D,Jin X,Li F,et al.Integrin αvβ3 imaging of radioactive iodine-refractory thyroid cancer using 99mTc-3PRGD2[J].J Nucl Med,2012,53(12):1872-1877.
10 Li Q,Zhang Y,El-Naggar AK,et al.Therapeutic efficacy of p53 restoration in mdm2-overexpressing tumors[J].Molecular Cancer Research Mcr,2014,12(6):901-911.
11 Jing FJ,Liang J,Liang ZY,et al.BRAFV600E mutation is not a positive predictor for distant metastasis in sporadic papillary thyroid carcinoma[J].Chin Med J,2013,126(16):3013-3018.
12 Durante C,Hanndy N,Baudin E,et al.Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma:benefits and limits of radioiodine therapy[J].J Clin Endocrinol Metab,2006,91(8):2892-2899.
13 Demaria S,Ng B,Devitt ML,et al.Ionizing radiation inhibition of distant untreated tumors(abscopal effect)is immune mediated[J].Int J Radiat Oncol,2004,58(3):862-870.
14 Li J,Qin S,Xu J,et al.Randomized,double-blind,placebo-controlled phase Ⅲ trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction[J].J Clin Oncol,2016,34(13):1448-1454.
15 Schlumberger M,Brose M,Eliset R,et al.Definition and management of radioactive iodine-refractory differentiated thyroid cancer[J].Lancet Diabetes Endocrinol,2014,2(5):356-358.

[1]	梁洁, 王新华, 王健, 夏欢. 非远处转移性甲状腺乳头状癌¹³¹I疗效预测模型的分析[J]. 实用肿瘤学杂志, 2022, 36(3): 220-225.
[2]	孙元元, 张苧之, 曹孟儒. 乳腺癌肺转移机制及治疗进展[J]. 实用肿瘤学杂志, 2022, 36(2): 173-177.
[3]	吴丹, 王路, 王兴华, 崔亚利. ¹³¹I联合甲磺酸阿帕替尼对难治性甲状腺癌细胞的抑制作用及机制研究[J]. 实用肿瘤学杂志, 2020, 34(2): 139-143.
[4]	孔繁巍综述, 赵长久审校. 分化型甲状腺癌碘131治疗后的外周血细胞改变[J]. 实用肿瘤学杂志, 2018, 32(5): 476-479.
[5]	程卫,赵华. 重组人促甲状腺激素辅助¹³¹I在儿童和青少年分化型甲状腺癌的临床研究[J]. 实用肿瘤学杂志, 2016, 30(4): 309-313.
[6]	王迪¹, 何月涵², 王兴华¹, 于红波¹, 王玉君¹, 崔亚利¹. 青少年分化型甲状腺癌¹³¹I治疗的临床观察[J]. 实用肿瘤学杂志, 2015, 29(3): 193-196.
[7]	范春花, 崔贤杰, 杨廷强, 杨洪英. 长春瑞滨联合顺铂治疗鼻咽癌伴肺转移的临床观察[J]. 实用肿瘤学杂志, 2008, 22(6): 546-547.
[8]	王玉君;赵彦辉;崔亚利. 99mTc-MIBI全身显像在131I治疗分化型甲状腺癌转移灶中的应用价值[J]. 实用肿瘤学杂志, 2008, 22(04): 337-338.
[9]	张秀春. 多西紫杉醇联合希罗达治疗乳腺癌肺转移39例临床分析[J]. 实用肿瘤学杂志, 2008, 22(01): 26-28.
[10]	娄长杰;张清媛;赵文辉. 乳腺癌发生脑转移的相关因素分析[J]. 实用肿瘤学杂志, 2006, 20(02): 93-96.
[11]	陈彦凡;陈少贤. 甲状腺癌肺转移11例临床分析[J]. 实用肿瘤学杂志, 2001, 15(01): 38-39.

¹³¹I联合甲磺酸阿帕替尼治疗分化型甲状腺癌肺转移的短期疗效及安全性研究

Short-term efficacy and safety of ¹³¹I combined with apatinib in the treatment of differentiated thyroid cancer with lung metastasis

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 11

编辑推荐

Metrics

本文评价